EBI-2511

N/A

Report date: 2022/06/29 15:08:18
NME

Base Information

Drug NameEBI-2511
Drug Alias NameEBI-2511
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Hengrui Pharmaceutical Co LtdEternity Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesEternity Bioscience IncShanghai Hengrui Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A